Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Dry Mass
100%
Multiple Myeloma
100%
Volume Change
100%
Mass Change
100%
Myeloma Cells
100%
Genotoxic Drugs
100%
Proteotoxic
100%
Bortezomib
57%
Apoptosis
28%
RPMI8226
28%
MM.1S
28%
Microscopic Techniques
14%
Highly Effective
14%
Doxorubicin
14%
Label-free
14%
Protease Inhibitors
14%
Accurate Identification
14%
Optical Microscopy
14%
Overall Survival of Patients
14%
Cell-derived
14%
Apoptotic Cells
14%
Acquired Resistance
14%
Complex Behavior
14%
Rapid Assay
14%
Complex Kinetics
14%
Plasma Cells
14%
Novel Agents
14%
Quantitative Phase Microscopy
14%
Early Response
14%
Phase Sensitive
14%
Volume Measurement
14%
Limited Samples
14%
Cell Studies
14%
Mass Increase
14%
Dry Mass Measurement
14%
Multiple Myeloma Patients
14%
Prolonged Treatment
14%
Nonresponsive Patients
14%
Volume Decrease
14%
Immunosuppressive Agents
14%
Coulter Counter
14%
Digital Holographic Tomography
14%
Immunology and Microbiology
Dry Mass
100%
Multiple Myeloma
100%
Myeloma Cell
100%
Light Microscopy
12%
Proteasome
12%
Overall Survival
12%
Multiple Myeloma Cell Line
12%
Immunoglobulin Producing Cell
12%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Bortezomib
50%
Biological Marker
25%
Malignant Neoplasm
12%
Overall Survival
12%
Doxorubicin
12%
Proteasome Inhibitor
12%
Microscopy
12%
Biochemistry, Genetics and Molecular Biology
Dry Mass
100%
Proteasome Inhibitor
12%
Overall Survival
12%
Optics
12%
Microscopy
12%
Doxorubicin
12%
Immunoglobulin Producing Cell
12%